Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Discharge 39% Improvement Relative Risk HCQ for COVID-19  Taieb et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 926 patients in Senegal Higher discharge with HCQ (p=0.017) Taieb et al., J. Clin. Med. 2021, June 2021 Favors HCQ Favors control

Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020

Taieb et al., J. Clin. Med. 2021, doi:10.3390/jcm10132954
Jun 2021  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 926 patients in Senegal, 674 treated with HCQ+AZ, showing significantly higher hospital discharge at day 15 with treatment.
risk of no hospital discharge, 38.7% lower, OR 0.61, p = 0.02, treatment 674, control 252, inverted to make OR<1 favor treatment, multivariate, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Taieb et al., 30 Jun 2021, retrospective, Senegal, peer-reviewed, 29 authors, average treatment delay 6.0 days.
This PaperHCQAll
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
Fabien Taieb, Khardiata Diallo Mbaye, Billo Tall, Ndèye Aïssatou Lakhe, Cheikh Talla, Daouda Thioub, Amadou Moustapha Ndoye, Daye Ka, Aboubacry Gaye, Viviane Marie-Pierre Cissé Diallo, Ndongo Dia, Pape Samba Ba, Mamadou Cissé, Moustapha Diop, Cheikh Tidiane Diagne, Louise Fortes, Mamadou Diop, Ndèye Maguette Fall, Fatoumata Diène Sarr, Margarite Diatta, Mamadou Aliou Barry, Aboubakar Sidikh Badiane, Abdoulaye Seck, Philippe Dubrous, Ousmane Faye, Inès Vigan-Womas, Cheikh Loucoubar, Amadou Alpha Sall, Moussa Seydi
Journal of Clinical Medicine, doi:10.3390/jcm10132954
As of today, little data is available on COVID-19 in African countries, where the case management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19 hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus AZM and those who did not receive this combination. A total of 926 patients were included in this analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM. Results showed that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63, IC 95% (1.09-2.43)). Factors associated with a lower proportion of patients discharged alive were: age ≥ 60 years (OR: 0.55, IC 95% (0.36-0.83)), having of at least one pre-existing disorder (OR: 0.61, IC 95% (0.42-0.90)), and a high clinical risk at admission following NEWS score (OR: 0.49, IC 95% (0.28-0.83)). Few side effects were reported including 2 cases of cardiac rhythmic disorders in the HCQ and AZM group versus 13 in without HCQ + AZM. An improvement of clinical status at 15 days was found for patients exposed to HCQ plus AZM combination.
Conflicts of Interest: The authors declare no conflict of interest.
Andreani, Le Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb. Pathog, doi:10.1016/j.micpath.2020.104228
Arshad, Kilgore, Chaudhry, Jacobsen, Wang et al., Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.06.099
Bacharier, Guilbert, Mauger, Boehmer, Beigelman et al., Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children with a History of Such Illnesses: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2015.13896
Belayneh, Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation, Res. Rep. Trop. Med, doi:10.2147/rrtm.s269936
Bessière, Roccia, Delinière, Charrière, Chevalier et al., Assessment of QT Intervals in a Case Series of Patients with Coronavirus Disease 2019 (COVID-19) Infection Treated with Hydroxychloroquine Alone or in Combination with Azithromycin in an Intensive Care Unit, JAMA Cardiol, doi:10.1001/jamacardio.2020.1787
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2019014
Core, R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing
Dagens, Sigfrid, Cai, Lipworth, Cheung et al., Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: Rapid review, BMJ, doi:10.1136/bmj.m1936
Damle, Vourvahis, Wang, Leaney, Corrigan, Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19, Clin. Pharmacol. Ther, doi:10.1002/cpt.1857
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105938
Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study, BMJ, doi:10.1136/bmj.m1985
Gautret, Hoang, Lagier, Raoult, Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106239
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: Building an international community of software platform partners, J. Biomed. Inform
Hoehl, Rabenau, Berger, Kortenbusch, Cinatl et al., Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China, N. Engl. J. Med, doi:10.1056/NEJMc2001899
Horby, Mafham, Linsell, Bell, Staplin et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med, doi:10.1056/nejmoa2022926
Huang, Soleimani, Herasevich, Pinevich, Pennington et al., Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review, Mayo Clin. Proc, doi:10.1016/j.mayocp.2020.10.022
Isaric, Novel Coronavirus (NCoV) Acute Respiratory Infection Clinical Characterisation Data Tool, Version
Jensen, Mehlhorn, Seventy-five years of Resochin®in the fight against malaria, Parasitol. Res, doi:10.1007/s00436-009-1524-8
Jombart, Procter, Knight, COVID-19 length of hospital stay: A systematic review and data synthesis, BMC Med, doi:10.1186/s12916-020-01726-3
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101791
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Million, Gautret, Colson, Roussel, Dubourg et al., Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between the big data and the real world, New Microbes New Infect, doi:10.1016/j.nmni.2020.100709
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med. Infect. Dis, doi:10.1016/j.tmaid.2020.101738
Mitjà, Corbacho-Monné, Ubals, Tebé, Peñafiel et al., Hydroxychloroquine for Early Treatment of Adults with Mild Coronavirus Disease 2019: A Randomized, Controlled Trial, Clin. Infect. Dis, doi:10.1093/cid/ciaa1009
Nachega, Ishoso, Otokoye, Hermans, Machekano et al., Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo, Am. J. Trop. Med. Hyg, doi:10.4269/ajtmh.20-1240
Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results, N. Engl. J. Med, doi:10.1056/nejmoa2023184
Rees, Nightingale, Jafari, Waterlow, Clifford et al., None
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Rosenthal, Cao, Gundrum, Sianis, Safo, Risk Factors Associated with In-Hospital Mortality in a US National Sample of Patients With COVID-19, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.29058
Simpson, Beever, Challen, De Angelis, Fragaszy et al., The UK's pandemic influenza research portfolio: A model for future research on emerging infections, Lancet Infect. Dis, doi:10.1016/S1473-3099(18)30786-2
Smohas, Coronavirus (COVID-19) Situation Dashboard
Stokkermans, Goyal, Bansal, Trichonas, Chloroquine and Hydroxychloroquine Toxicity
Trape, Pison, Preziosi, Enel, Du Loû et al., Impact of chloroquine resistance on malaria mortality, Comptes Rendus Acad. Sci. Ser. III Sci. Vie, doi:10.1016/S0764-4469(98)80009-7
Trape, Tall, Sokhna, Ly, Diagne et al., The rise and fall of malaria in a west African rural community, Dielmo, Senegal, from 1990 to 2012: A 22 year longitudinal study, Lancet Infect. Dis, doi:10.1016/S1473-3099(14)70712-1
Trape, The public health impact of chloroquine resistance in Africa, Am. J. Trop. Med. Hyg, doi:10.4269/ajtmh.2001.64.12
Who Who Director, s Opening Remarks at the Media Briefing on COVID-19-11
Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop